Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Probenecid | The serum concentration of Cefpodoxime can be increased when it is combined with Probenecid. |
| Foscarnet | The risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Foscarnet. |
| Mannitol | The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefpodoxime. |
| Tenofovir disoproxil | Cefpodoxime may increase the nephrotoxic activities of Tenofovir disoproxil. |
| Tenofovir alafenamide | Cefpodoxime may increase the nephrotoxic activities of Tenofovir alafenamide. |
| Tenofovir | Cefpodoxime may increase the nephrotoxic activities of Tenofovir. |
| Olanzapine | Olanzapine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cimetidine | Cimetidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nizatidine | Nizatidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ranitidine | Ranitidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Famotidine | Famotidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methantheline | Methantheline can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Promethazine | Promethazine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Doxepin | Doxepin can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Asenapine | Asenapine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Metiamide | Metiamide can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Roxatidine acetate | Roxatidine acetate can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lafutidine | Lafutidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lavoltidine | Lavoltidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Niperotidine | Niperotidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Epinastine | Epinastine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium oxide | The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium oxide. |
| Sodium bicarbonate | The serum concentration of Cefpodoxime can be decreased when it is combined with Sodium bicarbonate. |
| Aluminum hydroxide | The serum concentration of Cefpodoxime can be decreased when it is combined with Aluminum hydroxide. |
| Calcium carbonate | The serum concentration of Cefpodoxime can be decreased when it is combined with Calcium carbonate. |
| Magaldrate | The serum concentration of Cefpodoxime can be decreased when it is combined with Magaldrate. |
| Magnesium hydroxide | The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium hydroxide. |
| Magnesium trisilicate | The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium trisilicate. |
| Magnesium carbonate | The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium carbonate. |
| Bismuth subnitrate | The serum concentration of Cefpodoxime can be decreased when it is combined with Bismuth subnitrate. |
| Magnesium silicate | The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium silicate. |
| Aluminium acetoacetate | The serum concentration of Cefpodoxime can be decreased when it is combined with Aluminium acetoacetate. |
| Hydrotalcite | The serum concentration of Cefpodoxime can be decreased when it is combined with Hydrotalcite. |
| Magnesium peroxide | The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium peroxide. |
| Almasilate | The serum concentration of Cefpodoxime can be decreased when it is combined with Almasilate. |
| Aluminium glycinate | The serum concentration of Cefpodoxime can be decreased when it is combined with Aluminium glycinate. |
| Aloglutamol | The serum concentration of Cefpodoxime can be decreased when it is combined with Aloglutamol. |
| Calcium silicate | The serum concentration of Cefpodoxime can be decreased when it is combined with Calcium silicate. |
| Aluminium phosphate | The serum concentration of Cefpodoxime can be decreased when it is combined with Aluminium phosphate. |
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefpodoxime. |
| Cyclosporine | The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpodoxime. |
| Icosapent | The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Cefpodoxime. |
| Cefotiam | The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Cefpodoxime. |
| Mesalazine | The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefpodoxime. |
| Cefmenoxime | The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Cefpodoxime. |
| Cefmetazole | The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Cefpodoxime. |
| Indomethacin | The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefpodoxime. |
| Triamterene | The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Cefpodoxime. |
| Cefpiramide | The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Cefpodoxime. |
| Loracarbef | The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefpodoxime. |
| Cefalotin | The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Cefpodoxime. |
| Nabumetone | The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Cefpodoxime. |
| Ketorolac | The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Cefpodoxime. |
| Tenoxicam | The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Cefpodoxime. |
| Celecoxib | The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Cefpodoxime. |
| Cefotaxime | The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefpodoxime. |
| Tolmetin | The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Cefpodoxime. |
| Rofecoxib | The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Cefpodoxime. |
| Fenoprofen | The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Cefpodoxime. |
| Valdecoxib | The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Cefpodoxime. |
| Diclofenac | The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Cefpodoxime. |
| Sulindac | The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefpodoxime. |
| Bacitracin | The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Cefpodoxime. |
| Amphotericin B | The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefpodoxime. |
| Cephaloglycin | The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Cefpodoxime. |
| Adefovir dipivoxil | The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefpodoxime. |
| Pentamidine | The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Cefpodoxime. |
| Mefenamic acid | The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Cefpodoxime. |
| Naproxen | The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefpodoxime. |
| Sulfasalazine | The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefpodoxime. |
| Phenylbutazone | The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Cefpodoxime. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Cefpodoxime is combined with Meloxicam. |
| Carprofen | The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Cefpodoxime. |
| Tacrolimus | The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefpodoxime. |
| Etacrynic acid | The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefpodoxime. |
| Ceforanide | The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Cefpodoxime. |
| Salicylic acid | The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Cefpodoxime. |
| Acetylsalicylic acid | The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefpodoxime. |
| Hydrochlorothiazide | The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Cefpodoxime. |
| Balsalazide | The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Cefpodoxime. |
| Cefditoren | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Cefpodoxime. |
| Atazanavir | The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Cefpodoxime. |
| Colistimethate | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefpodoxime. |
| Cefuroxime | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Cefpodoxime. |
| Cefapirin | The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Cefpodoxime. |
| Cefprozil | The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Cefpodoxime. |
| Olsalazine | The risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Olsalazine. |
| Lumiracoxib | The risk or severity of nephrotoxicity can be increased when Lumiracoxib is combined with Cefpodoxime. |
| Cefamandole | The risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Cefpodoxime. |
| Cefazolin | The risk or severity of nephrotoxicity can be increased when Cefazolin is combined with Cefpodoxime. |
| Cefonicid | The risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Cefpodoxime. |
| Cefoperazone | The risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Cefpodoxime. |
| Cefoxitin | The risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Cefpodoxime. |
| Ceftizoxime | The risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Cefpodoxime. |
| Magnesium salicylate | The risk or severity of nephrotoxicity can be increased when Magnesium salicylate is combined with Cefpodoxime. |
| Salsalate | The risk or severity of nephrotoxicity can be increased when Salsalate is combined with Cefpodoxime. |
| Choline magnesium trisalicylate | The risk or severity of nephrotoxicity can be increased when Choline magnesium trisalicylate is combined with Cefpodoxime. |
| Cefepime | The risk or severity of nephrotoxicity can be increased when Cefepime is combined with Cefpodoxime. |
| Cefacetrile | The risk or severity of nephrotoxicity can be increased when Cefacetrile is combined with Cefpodoxime. |
| Antrafenine | The risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Antrafenine. |